CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 20,123,400 shares, a growth of 15.0% from the December 15th total of 17,499,100 shares. Based on an average daily trading volume, of 6,176,200 shares, the short-interest ratio is currently 3.3 days.
CytoDyn Stock Up 1.3 %
CYDY traded up $0.00 during trading on Friday, hitting $0.15. The company had a trading volume of 1,217,001 shares, compared to its average volume of 2,325,929. The company has a market capitalization of $185.14 million, a PE ratio of -7.54 and a beta of -0.10. CytoDyn has a one year low of $0.10 and a one year high of $0.32. The firm's 50-day moving average price is $0.12 and its 200 day moving average price is $0.14.
About CytoDyn
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
